Effectiveness and survival of methotrexate versus adalimumab in patients with moderate-to-severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)
BJD, 2023.
Alabas OA, Mason KJ, Yiu ZZN, Warren RB, Lunt M, Smith CH, Griffiths, CEM; BADBIR Study Group
Read publication: BJD
Related
Uptake of tumour necrosis factor - alpha inhibitor biosimilars for psoriasis: A drug utilisation stu...
Differences in Clinical Features and Comorbid Burden between HLA-C∗06:02 Carrier Groups in >9,000...
Characteristics and skin cancer risk of psoriasis patients with a history of skin cancer in BADBIR
0 Comments